
Aarvik Therapeutics Secures Funding with Successful Series Seed 2 Round
Aarvik Therapeutics Closes Series Seed 2 Financing Round, Accelerating Development of Next-Generation Cancer Therapies Aarvik Therapeutics, a pioneering biotechnology company specializing in antibody-drug conjugates (ADCs) and committed to advancing precision medicine in oncology, has announced the successful completion of its…












